Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing As Usual in Psychiatric Disorders

Not Applicable

Recruiting

• Conditions: Anxiety Disorders; Mood Disorders; Psychotic Disorders
• Interventions: Other: Personalised medication advice based on pharmacogenetic testing

• Registration Number: NCT05656469
• Lead Sponsor: Maastricht University Medical Center

Brief Summary

A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.

Detailed Description

Effective pharmacotherapeutic treatments for mental disorders are available, but their effectiveness is limited by low compliance due to frequent side effects. This is partly due to patient heterogeneity in the genes encoding for drug-metabolising enzymes. Pharmacogenetic testing allows the assessment of person-specific genetic factors that are thought to predict clinical response and side effects. Recent studies have suggested that genotyping genes encoding drug-metabolizing enzymes may improve treatment efficacy and tolerability, potentially benefitting millions of patients.

PSY-PGx is the first initiative to propose a large-scale non-industry sponsored clinical study that aims to demonstrate the clinical benefits and potential of the implementation of pharmacogenetics for psychiatric patients in existing medical settings.

This is an international 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.

Study Timeline

• Study First Submitted: 2022-11-30
• Study First Submitted QC: 2022-12-09
• Study First Posted: 2022-12-19
• Study Start: 2023-02-23
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-23
• Last Update Posted: 2024-10-26
• Primary Completion: 2025-03
• Study Completion: 2025-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2500

Inclusion Criteria

1. Suffer from a depressive episode (major depressive disorder and bipolar disorder (currently depressive episode)) (as assessed by the MINI International Neuropsychiatric Interview (M.I.N.I.) in agreement with Diagnostic and Statistical Manual (DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Depression Scale (SIGH-D) with a score of 14 or higher) and/or suffer from an anxiety disorder (panic disorder, generalised anxiety disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH- A) with a score of 18 or higher) and/or suffer from a psychotic disorder (schizophrenia and schizoaffective disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Positive and Negative Symptom Scale (PANSS) with a score of 75 or higher).
2. Have had an inadequate response to at least 1 psychotropic treatment during their life-time. Inadequate response is defined as insufficient efficacy of a psychotropic treatment when dosed high enough and maintained long enough, or discontinuation of a psychotropic treatment due to AEs or intolerability.
3. Are about to switch (or have switched within the last 2 weeks prior to first contact with an investigator) to sertraline or escitalopram (for patients with mood or anxiety disorders), or to aripiprazole or risperidone (for patients with psychotic disorders) due to an inadequate response to or intolerance of the current/ previous medication.
4. Currently receiving inpatient or outpatient psychiatric treatment.
5. Be able to understand the requirements of the study and provide written informed consent to participate in this study; a signed and dated informed consent form (ICF) will be obtained from each patient before participation in the study.
6. To give written consent to the use and disclosure of clinical data from their medical records for the purpose of this study.
7. Age between ≥16 and <65 years.
8. Ownership of a mobile phone (Android or iOS operation system) for passive monitoring.

Exclusion Criteria

1. Patients with a history of prior pharmacogenomic testing

2. Patients with no prior use of psychotropic medication (medication-naïve patients)

3. Severe somatic comorbidities as reported in the subject's medical history or based on clinical chemistry/electrocardiography (ECG) results up to six months ago. If any of these comorbidities is detected on the basis of physical examination and/or clinical chemistry and/or ECG at the screening visit, participation is not possible.

   • Liver disease defined as follows: Alanine-Aminotransferase (ALAT) >70u/L
   • Renal disease: Estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2
   • Diabetes: Blood glucose > 11.1 mmol/L or twice a fasting glucose > 7.0 mmol/L
   • Cardiac disease: prolonged QT-interval.

4. Alcohol and/or substance abuse and/or dependence (except nicotine)

5. Polypharmacy defined as the routine use of five or more medications including over- the-counter, prescription and/or traditional and complementary medicines used by a patient (WHO 2019).

6. Inability to use the mobile phone application

7. Pregnant or breastfeeding women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
PSY-PGx Group	Personalised medication advice based on pharmacogenetic testing	This is the intervention group. All patients will be treated according to a personalised medication recommendation based on the results of pharmacogenetic testing, following the prespecified dosing guideline. Prescribing physicians will prescribe one of the predefined drugs and will be unblinded for genotype and the resulting metabolisation phenotype.

Primary Outcome Measures

Name	Time	Method
Patient recovery, as assessed using the Patient Recovery Assessment scale - Domains and Stages (RAS-DS).	24 weeks	A standardised self-report tool that measures mental health recovery as defined by the client. Repeated use of the instrument makes it possible to detect change over time.; Score range 38-152. Higher scores mean a better outcome.

Secondary Outcome Measures

Name	Time	Method
Symptomatic Remission Mood Disorder, defined as:	24 weeks	SIGH-D score of 7 or less. Score range 0-52. Higher scores mean a worse outcome.
Response Psychotic Disorder, defined as a 50% point reduction in the following scale:	24 weeks	Positive and Negative Symptom Scale (PANSS) for psychotic disorder. Score range 30-210. Higher scores mean a worse outcome.
Symptomatic Remission Psychotic Disorder, defined as:	24 weeks	PANSS score of 57 or less. Score range 30-210. Higher scores mean a worse outcome.
Burden of side effects, as measured by:	24 weeks	Frequency, Intensity and Burden of side effects ratings (FIBSER). Score range 0-18. Higher scores mean a worse outcome.
Side effects, as measured by:	24 weeks	Udvalg for Kliniske Undersogelse - Side Effects Rating Scale (UKU-SERS). Score range 0-135. Higher scores mean a worse outcome.
Response Mood Disorder, defined as a 50% point reduction in the following scale:	24 weeks	Structured interview Guide for the Hamilton Depression Scale (SIGH-D) for depressive disorder.; Score range 0-52. Higher scores mean a worse outcome.
Response Anxiety Disorder, defined as a 50% point reduction in the following scale:	24 weeks	Structured interview Guide for the Hamilton Anxiety Scale (SIGH-A) for anxiety disorder. Score range 0-56. Higher scores mean a worse outcome.
General wellbeing, as measured by:	24 weeks	The 5-level EQ-5D version (EQ-5D-5L). Score range 5-25. Higher scores mean a worse outcome. Visual Analog Scale (VAS)-score 0-100. A higher score means a better outcome.
Symptomatic Remission Anxiety Disorder, defined as:	24 weeks	SIGH-A score of 7 or less. Score range 0-56. Higher scores mean a worse outcome.
Psychosocial functioning, as measured by:	24 weeks	Functioning Assessment short test (FAST). Score range 0-72. Higher scores mean a worse outcome.

Trial Locations

Locations (9)

SUNY Upstate Medical University, Department of Psychiatry and Behavioural Sciences; 🇺🇸 Syracuse, New York, United States

University Hospital Bonn, Department of Psychiatry and Psychotherapy; 🇩🇪 Bonn, Germany

Ludwig-Maximilian University, University Hospital, Institute of Psychiatric Phenomics and Genomics (IPPG); 🇩🇪 München, Germany

Parnassia Psychiatric Institute, Department of Psychiatry; 🇳🇱 Amsterdam, Netherlands

Maastricht University, Department of Psychiatry and Neuropsychology; 🇳🇱 Maastricht, Netherlands

Babeş-Bolyai University, Department of Clinical Psychology and Psychotherapy; 🇷🇴 Cluj-Napoca, Romania

University of Belgrade, Faculty of Pharmacy; 🇷🇸 Belgrade, Serbia

Fundació Clínic per a la Recerca Biomèdica, Department of Psychiatry and Psychology, Hospital Clínic; 🇪🇸 Barcelona, Spain

King's College, Institute of Psychiatry, Psychology & Neuroscience; 🇬🇧 London, United Kingdom